Michael Lee has over 20 years of experience in auditing, investment banking, and investment. He currently serves as a director, general manager, and investment committee member of the fund management company.
Michael Lee joined China International Capital Corporation (CICC) in 2007. From May 2007 to July 2015, he was Managing Director in the Investment Banking Department. He later served as Managing Director of the Investment Fund Department at CICC Capital Operation Co., Ltd., and General Manager of Yaojin (Shanghai) Private Equity Fund Management Co., Ltd. (formerly Sinopharm CICC).
During his tenure at CICC, Michael Lee was responsible for the Zhejiang region and worked with China National Pharmaceutical Group Corporation (Sinopharm), completing multiple capital operations within the Sinopharm system as well as projects such as the listing of Zheneng Power.
While at CICC Zhizhi, he led landmark investments in companies such as East Sunshine Pharmaceutical, Ant Financial, CNPC Pipeline, YTO Express, Wanda Pictures, and Cloud Technology.
At Yaojin Capital, Mr. Li is fully responsible for fundraising, investment, management, and exit. Under his leadership, the firm has completed investments in projects including United Imaging Healthcare, Jilin Tianhe, FeiPeng Bio, Guangzhou Conotec, Dingdang Kuaiyao, Sinopharm Innovation & Technology, Sinopharm Geno, MicuRx Pharmaceuticals, TengRui Pharma, Hefei Medical, Kejin Biotech, Zhongsheng Tianxinhe, Mingzhi Medical, Chenxi Technology, Ruizhi Technology, Pinchi Medical, Memed Medical, and Meimu Meijia.
李可先生拥有超过20年的审计、投资银行和投资经验，目前任基金管理公司董事、总经理、投委会委员。李先生自2007年加入中国国际金融股份有限公司，自2007年5月-2015年7月任投资银行部董事总经理，之后任中金资本运营有限公司投资基金部董事总经理、曜金（上海）私募基金管理有限公司（原国药中金）总经理。李可先生在中金公司期间，担任浙江地区负责人，并服务中国医药集团总公司，完成国药体系多个资本运作和浙能电力上市等项目。在中金智德期间，李先生主导投资了东阳光药业、蚂蚁金服、中石油管道、圆通速递、万达影业、光云科技等里程碑项目。在曜金资本期间，李先生全面负责基金募投管退，其领导并完成的投资项目包括上海联影、吉林天和、菲鹏生物、广州康诺、叮当快药、国控创服创科、国药洁诺、盟科药业、腾瑞制药、合富医疗、科进生物、中生天信和、明智医疗、宸汐科技、睿视科技、品驰医疗、美目美佳等项目。

Elaine Sun founded UP Medical in 2014 and serves as its chairman. She graduated from the University of Sydney with a Bachelor's and Master's degrees in Business and Law, as well as a Doctor of Business Administration and Law.
She founded the first rehabilitation and sports medicine medical centre in China, introducing the world's leading sports medicine system to the country. She popularised the concept of sports rehabilitation, promoted the development of China's sports rehabilitation industry, and helped sports rehabilitation become an integral part of a healthy lifestyle.

孙晓怡女士于2014年创办优复医疗，并担任董事长。她毕业于悉尼大学，拥有商学、法学本科和硕士学位，以及工商管理与法学博士学位。
她创办的优复医疗，打造了全国首家康复医疗中心，把全球领先的运动康复体系引入国内，普及运动康复理念，推动中国运动康复行业发展，引领运动康复成为一种健康生活方式

Chloe Chen joined AIER Eye Hospital Group in June 2015, where she played an integral role in all of AIER’s overseas mergers and acquisitions (M&A). She co-led the acquisition of the CLINICA BAVIERA Group in Spain and ISEC Healthcare Ltd. in Singapore.
She represented AIER at the World Association of Eye Hospitals (WAEH) and played a pivotal role in AIER becoming the only Chinese board member among the eight members of the WAEH Board.
Currently, she is responsible for overseeing AIER's international individual and institutional collaboration projects at the group level. By organising and hosting more than a hundred academic conferences, she has provided a platform for domestic and international experts to exchange knowledge and ideas. Additionally, she has worked to elevate AIER’s global presence by strengthening partnerships with international organisations.
Chloe Chen 2015年6月加入爱尔眼科医院集团，参与了集团所有海外收并购项目，并共同主导了对西班牙CLINICA BAVIERA眼科集团和新加坡ISEC医疗集团的收购。
她代表爱尔眼科参与了世界眼科医院协会（WAEH）的相关活动，并成功推动爱尔成为WAEH八席董事会成员中唯一的中国成员。
目前，负责爱尔眼科集团层面的国际专家及机构合作事务。通过组织和推动举办逾百场学术会议，为国内外专家提供了一个知识交流与合作的平台。同时，她还通过加强与国际组织的联系，持续推动爱尔眼科在全球舞台的影响力和合作关系。

郭威廷Weiting Kuo医生，中国台湾籍，拥有武汉大学口腔临床医学博士学位（DDS, M.D.），专精牙体牙髓领域。他不仅是法国赛普敦（Septodont）中国区合作讲师，其优秀病例更被收录于官方病例集。


郭医生兼具深厚的国际视野，曾赴西班牙、法国、新加坡进行种植专项进修。他拥有多项国际权威认证：Straumann SAC-C 高级种植医师、Osstem大师班种植医师、Ivoclar瓷贴面美学修复医师、Bondent显微根管治疗医师，以及Invisalign隐适美和LM罗慕矫正认证医师。同时，他也是华人美学牙科协会会员。


Dr. Weiting Kuo, a native of Taiwan, holds a Doctor of Dental Surgery (DDS, M.D.) degree from Wuhan University and specializes in the field of dental pulp and endodontics. He is not only a collaborative lecturer for Septodont in China but also has his outstanding cases included in the official case collection. 


Dr. Kuo possesses a profound international perspective, having furthered his studies in implant dentistry in Spain, France, and Singapore. He holds multiple prestigious international certifications: Straumann SAC-C Advanced Implant Surgeon, Osstem Masterclass Implant Surgeon, Ivoclar Esthetic Restoration Dentist, Bondent Microscope Endodontist, as well as certifications in Invisalign and LM orthodontics. Additionally, he is a member of the Chinese Aesthetic Dentistry Association.

Liu Tie serves as the COO and Head of CMC at Shentuo Biotech, where he is leading the development of a first-in-class gene therapy for neurofibromatosis type 2 (NF2). Previously, he worked at Merck/BioReliance and AstraZeneca as a senior analytical scientist. He also held managerial roles at multinational pharmaceutical companies, including Pfizer and Bristol Myers Squibb (BMS), bringing with him more than 20 years of experience in biologics CMC.
他目前担任神拓生物的首席运营官（COO）兼CMC负责人，正在主导开发针对神经纤维瘤2型（NF2）的全球首创基因疗法。此前，他曾在Merck/BioReliance和阿斯利康担任资深分析科学家，并在辉瑞和百时美施贵宝（BMS）等跨国制药企业担任管理职务，拥有超过20年的生物药CMC经验。

Helen Jiang is the Founder of BioClub and BioClub Capital, and currently serves as the Secretary-General of the Minhang District Health Industry Alliance in Shanghai. Recognised as a National Outstanding Innovation and Entrepreneurship Mentor by the Ministry of Education, Helen is also an Off-Campus MBA Mentor at Zhejiang University. With more than ten years of experience, she has focused on the fields of life and health within industrial communities, education and training, investment and mergers & acquisitions, and cross-border cooperation, achieving significant results across these areas.
Helen Jiang是贝壳社（BioClub）及贝壳资本的创始人，现任上海市闵行区工商联大健康产业联盟秘书长。作为教育部全国优秀创新创业导师，她同时担任浙江大学MBA校外导师。在产业社区大健康、教育培训、投资并购、跨境合作等领域深耕十余年，并取得了丰硕的成果。

Yi Yang has over 10 years of professional experience in driving business model innovation, business transformation, and tackling business growth and operational challenges in the Pharmaceutical, Medical Devices, and Healthcare Service industries. Yi Yang has a unique and proven track record in innovative product design and development, 0-1 digital business building, Digital Therapeutics (DTx) end-to-end process, and digital product launch. He has expertise in pricing and go-to-market strategy formulation and implementation, and has studied and worked in both mainland China and the US.
Yi Yang在医药、医疗器械和医疗服务行业拥有超过 10 年的专业经验，擅长驱动业务模式创新、业务转型，并解决企业业务增长和运营方面挑战。在创新产品设计&开发、0-1 数字业务构建、数字疗法 Digital
Therapeutics, DTx 搭建全流程和数字产品上市方面有独特且经过验证的业绩记录。熟悉产品定价和GTM 战略的制定和实施。在CSL Behring China 负责大中华区数字化与创新战略的制定与执行落地。
拥有纽约大学生物医学工程硕士学位，东北大学生物医学工程学士学位并曾在中国大陆和美国工作。